About Technology Issues FAQ

Links

Official Page

NanoString technology distinguishes anti‐TIF‐1γ⁺ from anti‐Mi‐2⁺ dermatomyositis patients

NanoString technology distinguishes anti‐TIF‐1γ<sup>+</sup> from anti‐Mi‐2<sup>+</sup> dermatomyositis patients — Distribution of the number of citations over years.

site/software © exaly; All materials licenced under CC by-SA.